Literature DB >> 23833241

Significant increase in plasma 4β-hydroxycholesterol concentration in patients after kidney transplantation.

Yosuke Suzuki1, Hiroki Itoh, Fuminori Sato, Kanako Kawasaki, Yukie Sato, Takashi Fujioka, Yuhki Sato, Keiko Ohno, Hiromitsu Mimata, Satoshi Kishino.   

Abstract

Several previous studies have shown that renal failure decreases not only renal elimination but also metabolic clearance of drugs, particularly those metabolized by CYP3A. However, whether recovery of renal function results in recovery of hepatic CYP3A activity remains unknown. In this study, we evaluated the effect of renal function on CYP3A activity after kidney transplantation in patients with end-stage renal disease (ESRD) by measuring the change in CYP3A activity using plasma concentration of 4β-hydroxycholesterol as a biomarker. The study enrolled 13 patients with ESRD who underwent the first kidney allograft transplantation. Morning blood samples were collected before and 3, 7, 10, 14, 21, 30, 60, 90, 120, 150 and 180 days after kidney transplantation. Plasma concentration of 4β-hydroxycholesterol was measured using GC-MS. Compared with before kidney transplantation, creatinine clearance increased significantly from day 3 after kidney transplantation and stabilized thereafter. Plasma concentration of 4β-hydroxycholesterol was elevated significantly on days 90 and 180 after kidney transplantation. In conclusion, this study suggests the recovery of CYP3A activity with improvement in renal function after kidney transplantation in patients with ESRD.

Entities:  

Keywords:  CYP3A activity; end-stage renal disease; plasma; renal failure

Mesh:

Substances:

Year:  2013        PMID: 23833241      PMCID: PMC3735953          DOI: 10.1194/jlr.P040022

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  40 in total

1.  Endothelial functions improve with decrease in asymmetric dimethylarginine (ADMA) levels after renal transplantation.

Authors:  Mahmut Ilker Yilmaz; Mutlu Saglam; Kayser Caglar; Erdinc Cakir; Taner Ozgurtas; Alper Sonmez; Tayfun Eyileten; Mujdat Yenicesu; Cengizhan Acikel; Yusuf Oguz; Omer Ozcan; Ugur Bozlar; Kemal Erbil; Ismail Aslan; Abdulgaffar Vural
Journal:  Transplantation       Date:  2005-12-27       Impact factor: 4.939

Review 2.  Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes.

Authors:  D S Streetman; J S Bertino; A N Nafziger
Journal:  Pharmacogenetics       Date:  2000-04

3.  Effect of renal transplantation on biomarkers of inflammation and oxidative stress in end-stage renal disease patients.

Authors:  Edith M Simmons; Anthony Langone; M Tugrul Sezer; John P Vella; Peter Recupero; Jason D Morrow; T Alp Ikizler; Jonathan Himmelfarb
Journal:  Transplantation       Date:  2005-04-27       Impact factor: 4.939

4.  Metabolism of alprazolam (a marker of CYP3A4) in hemodialysis patients with persistent inflammation.

Authors:  Hadi Molanaei; Peter Stenvinkel; Abdul Rashid Qureshi; Juan Jesús Carrero; Olof Heimbürger; Bengt Lindholm; Ulf Diczfalusy; Ingegerd Odar-Cederlöf; Leif Bertilsson
Journal:  Eur J Clin Pharmacol       Date:  2011-12-09       Impact factor: 2.953

5.  Interleukin-2 receptor antibody-induced alterations of ciclosporin dose requirements in paediatric transplant recipients.

Authors:  J Strehlau; L Pape; G Offner; B Nashan; J H Ehrich
Journal:  Lancet       Date:  2000-10-14       Impact factor: 79.321

6.  Decreased in vivo metabolism of drugs in chronic renal failure.

Authors:  F A Leblond; L Giroux; J P Villeneuve; V Pichette
Journal:  Drug Metab Dispos       Date:  2000-11       Impact factor: 3.922

7.  Decrease in oral bioavailability of ciclosporin by intravenous pulse of methylprednisolone succinate in rats.

Authors:  Hiroki Konishi; Masaki Sumi; Nobuhito Shibata; Kanji Takada; Tokuzo Minouchi; Akira Yamaji
Journal:  J Pharm Pharmacol       Date:  2004-10       Impact factor: 3.765

8.  Changes of hepatic microsomal oxidative drug metabolizing enzymes in chronic renal failure (CRF) rats by partial nephrectomy.

Authors:  N Uchida; N Kurata; K Shimada; Y Nishimura; K Yasuda; M Hashimoto; E Uchida; H Yasuhara
Journal:  Jpn J Pharmacol       Date:  1995-08

9.  Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor pravastatin on urinary 6 beta-hydroxycortisol excretion: a preliminary study.

Authors:  U Karayalçin; Y Takeda; I Miyamori; T Morise; R Takeda
Journal:  Steroids       Date:  1991-12       Impact factor: 2.668

10.  Urinary excretion of 6 beta-hydroxycortisol as an in vivo marker for CYP3A induction: applications and recommendations.

Authors:  S J Kovacs; D E Martin; D E Everitt; S D Patterson; D K Jorkasky
Journal:  Clin Pharmacol Ther       Date:  1998-06       Impact factor: 6.875

View more
  5 in total

1.  The CYP3A biomarker 4β-hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation.

Authors:  Elisabet Størset; Kristine Hole; Karsten Midtvedt; Stein Bergan; Espen Molden; Anders Åsberg
Journal:  Br J Clin Pharmacol       Date:  2017-02-27       Impact factor: 4.335

2.  Pretransplant 4β-hydroxycholesterol does not predict tacrolimus exposure or dose requirements during the first days after kidney transplantation.

Authors:  Thomas Vanhove; Mahmoud Hasan; Pieter Annaert; Stefan Oswald; Dirk R J Kuypers
Journal:  Br J Clin Pharmacol       Date:  2017-07-14       Impact factor: 4.335

3.  CYP3A5 polymorphism affects the increase in CYP3A activity after living kidney transplantation in patients with end stage renal disease.

Authors:  Yosuke Suzuki; Takashi Fujioka; Fuminori Sato; Kunihiro Matsumoto; Nanako Muraya; Ryota Tanaka; Yuhki Sato; Keiko Ohno; Hiromitsu Mimata; Satoshi Kishino; Hiroki Itoh
Journal:  Br J Clin Pharmacol       Date:  2015-10-03       Impact factor: 4.335

4.  Sensitive UHPLC-MS/MS quantification method for 4β- and 4α-hydroxycholesterol in plasma for accurate CYP3A phenotyping.

Authors:  Yosuke Suzuki; Ayako Oda; Jun Negami; Daiki Toyama; Ryota Tanaka; Hiroyuki Ono; Tadasuke Ando; Toshitaka Shin; Hiromitsu Mimata; Hiroki Itoh; Keiko Ohno
Journal:  J Lipid Res       Date:  2022-02-16       Impact factor: 5.922

Review 5.  Recent advances in the translation of drug metabolism and pharmacokinetics science for drug discovery and development.

Authors:  Yurong Lai; Xiaoyan Chu; Li Di; Wei Gao; Yingying Guo; Xingrong Liu; Chuang Lu; Jialin Mao; Hong Shen; Huaping Tang; Cindy Q Xia; Lei Zhang; Xinxin Ding
Journal:  Acta Pharm Sin B       Date:  2022-03-17       Impact factor: 14.903

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.